Characteristics of food allergy in children: National multicenter study

Conference: Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) Location: Lisbon, PORTUGAL Date: JUN 01-05, 2019Background : Food allergies impose a significant burden on the life of the child and the family. In this study, to determine the demographic characteristics of food allergies, we investigated the characteristics of patients with food allergies in different regions of Pediatric Allergy- Immunology departments in Turkey. Method : Turkey ' s National Study of Allergy and Clinical Immunology Society has conducted a Study Group on Food Allergies. 25 centers participated in this multicenter, cross- sectional and descriptive study.European Academy of Allergy and Clinical Immunolog

Prevention of iron deficiency anemia in premature babies

Prematüre bebeklerin demir eksikliğinden korunmalarında, ilave demire en uygun başlanma zamanının saptanması amacıyla Mart 1983 - Ağustos 1984 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Kliniğinde yapılan bu çalışmada 34 hafta veya daha düşük gestasyonel yaşa sahip 52 prematüre bebek üç gurupta olmak üzere incelendiler, I. Guruptaki bebeklere bir aylıkta, II. Gurup taki bebeklere iki aylıkta, III, Guruptaki bebeklere de üç aylıkta ila ve demir verilmeye başlandı. Bebekler aylık kontrollerde ağırlık ve gelişim yönünden, 1., 2., 3. ve 6. aylarda da hematolojik yönden tetkik edildiler. Ağırlık artımı yönünden yapılan değerlendirmede bebekler arasında anlamlı farklılık saptanmadı» Hematolojik tetkiklerde ise, hemoglobin ve hematokrit değerleri 3 «aydaki ölçümlerde en geç ila ve demir başlanan gurupta diğer guruplara oranla düşük bulundu. Ancak bu guruba da ilave demir başlandıktan sonra altıncı ayda yapılan tetkiklerde arada fark kalmadığı görüldü. Serum demiri yönünden 3.ayda I. ve III.Gurup arasında anlamlı fark bulundu ve bu fark ilave demir başlandığı halde altıncı ayda halâ devam ediyordu. Ayrıca transferrin satürasyonu yönünden de en düşük değerler ilave demire eti geç başlanan gurupta elde edildi. Ancak bu değerler normal değerlerin alt sınırlarındaydı. MCV değerleri de 6, ayda en geç ilave demir başlanan gurup ta en düşük olarak bulundu ve diğer guruplarla anlamlı olarak farklıydı» Ancak yine de 6. ayda elde edilen bu değerler normal sınırlar için deydi. Birinci ve ikinci ayda ilave demir başlanan guruplar arasında sonuçlar yönünden anlamlı farklılık bulunamadı, fakat yine de birinci ay demir başlanan gurupta daha iyi sonuçlar elde edildi

Prevention of iron deficiency in premature infants

Prematüre bebeklerin demir eksikliğinden korunmalarında ilave demire en uygun başlama zamanının saptanması amacıyla yapılan bu çalışmada 34 hafta veya daha düşük gestasyonel yaşa sahip 52 prematüre bebek üç gruba ayrıldılar. I.Gruptaki bebeklere yaşamının 1'inci ayında, II. Gruptakilere 2'inci ayında ve III. Gruptakilere 3 'üncü ayında ağızdan demir verilmesine başlandı.Gruplar 6 ay süreyle her ay hematolojik yönden incelendiler. Yapılan incelemelerde, 3'üncü aya kadar demir verilmeyen III. Grupta, demir eksikliğinin yol açtığı eritrosit değişiklikleri 6 'ıncı ayda belirgin olarak ortaya çıktı. Bu bulgularla prematürelere ağızdan demir verilmesine 1-2 'inci aylar arasında başlanmasının doğru olacağı kanısına varıldı.This study was undertaken to determine the optimal postnatal age for the beginning of the oral iron supplementation in order to prevent iron deficiency anemia. For this purpose 52 infants with the gestational ages of 34 weeks or lower were divided into 3 groups. First group of infants were given oral iron supplementation at the age of one month, second group at the age of 2 months and third group at the age of 3 months. Red cell changes due to iron deficiency were apparent at the age of 6 months in the third group in which oral iron supplementation delayed until the third month of life. With these findings it was concluded that iron supplementation tation should be started between first and second months

Retrospective evaluation of cases with cow's milk allergy

Introduction: Cow's milk allergy (CMA) is described as immunological reaction against to one or more milk proteins. It is known that CMA which affects about 1-3% of the general population is the most commonly seen food allergy in infants and children. It is well known that a tolerance develops and prognosis is better during the first three years of the life. In the present study, we aimed to investigate the natural course of cases diagnosed with CMA and to determine the factors which have impact on the tolerance development.Materials and Methods: Medical records of cases who have been followed for CMA were retrospectively reviewed. Gender, age at first symptom, breastfeeding duration, family atopy history, multiple food allergies, concomitant allergic diseases, inhalant allergy sensitivity and clinical manifestation of cases were assessed. Also, prick test results, milk-specific IgE, casein-specific IgE and the reactions that developed during food challenge test were evaluated.Results: The age at first symptom was mean 4 +/- 2,3 months. Twenty-two percent of patients had a positive family history of atopy and 30% had multiple food allergies. There were concomitant allergic disorders in 58% of patients. Skin (93.8%), gastrointestinal system (GIS) (24.7%) and respiratory system (18.5%) symptoms were most commonly seen. The percentage of tolerance development by the years was determined as 41% for the first year, 64% for the second year and 75% for the third year. Milk-specific IgE level at the time of diagnosis (p=0.010) and asthma presence (p=0.010) were found significant risk factors for persistent CMA.Conclusion: Clinical parameters and allergy tests may help to predict the prognosis of CMA. Milk-specific IgE level at the time of diagnosis is the risk factor for persistent CMA

Omalizumab treatment in childhood chronic urticaria

Bu çalışma, 26-30, Mayıs 2018 tarihlerinde Munich[Almanya]’da düzenlenen Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) Kongresi‘nde bildiri olarak sunulmuştur.European Acad Allergy & Clin Immuno

The impact of the Covid-19 pandemic in adolescents with asthma

Background: The coronavirus disease 2019 (COVID-19) pandemic is affecting people at any age and there is limited information about the effect of the COVID-19 pandemic on quality of life (QoL) in adolescents with asthma. In the present study, it was aimed to assess the attitudes of adolescents with asthma toward the COVID-19 pandemic and determine the effects of the pandemic on their QoL. Methods: In total, 125 adolescents with asthma and 98 healthy adolescents participated in the present study. The questionnaire form consisted of three parts. In the first part, all the participants were asked whether they complied with the protective measures against COVID-19. The second part included questions for measuring the participants' level of concern about COVID-19, while the third part consisted of EUROHIS-QOL 8. Results: The patient and control groups were similar in terms of the female/male ratio (55/70 and 48/50, respectively) and mean participant age (14.6 +/- 2 and 15.1 +/- 1.65 years, respectively) (P = 0.459 and P = 0.062, respectively). The prevalence of COVID-19 in the patients (n = 2, 1.6%) was lower than that in the controls (n = 6, 6.1%); however, the difference was not statistically significant (P = 0.142). The total EUROHIS-QOL score was significantly lower in the patients (31.2 +/- 6.7) than in the controls (33.7 +/- 4.4) (P < 0.001). The total QoL scores of asthmatic adolescents without other allergic disease (31.4 +/- 6.7) was also lower than those of the controls (33.7 +/- 4.4) (P = 0.009). Treatment disruption was significantly more common in patients who received subcutaneous immunotherapy (n = 20, 48.8%) than in those who did not (n = 8, 9.5%) (P < 0.001). Moreover, the patients had lower EUROHIS-QOL scores in the overall QoL, general health, finance, and home domains. Conclusion: Our results indicate that the mean QoL score of asthmatic adolescents during COVID-19 pandemic is lower than in the healthy population. Disruption in their treatment was most common in patients with asthma who were receiving subcutaneous immunotherapy

Lung functions during long term follow-up after pleural empyema treatment in children

Introduction: Studies on lung functions at the long term follow-up of pleural empyema treatment in children are limited. The aim of this study was to evaluate the long term pulmonary function test results in childhood empyema cases treated with antibiotic (AB) or AB+tube thoracostomy (TT) or AB+TT+fibrinolytics (FT).Materials and Method: In this study, 45 cases (1 to 13 years old) treated for empyema were included. The age, gender, clinical characteristics, radiological findings and laboratory results at baseline and during the follow-up periods and the treatment modalities (AB or AB+TT or AB+TT+FT) were evaluated. Pulmonary function tests were performed at the end of the follow-up periods.Results: The mean ages at baseline and at the end of follow-up period of 30.4 +/- 13.5 (6-54) months were 6.3 +/- 3.3 (1-13) years and 9.3 +/- 3.4 (4-17) years, respectively. Stages of the disease at admission was acute exudative (stage 1) in 14 (31.1%) cases, fibrinopurulent (stage 2) in 19 (42.2%) and chronic organizing (stage 3) in 12 (26.7%). Twenty one cases (46.7%) were treated with AB, 8 (17.8%) with AB+TT and 16 (35.5%) with AB+TT+FT. Chest roentgenograms showed abnormal findings in 15 cases (33.3%) at the 3rd month, in 3 cases (6.6%) at the 6th month and none at the 12th month. Pulmonary function tests were available in 25 children. The mean follow-up period of these cases was 32.7 +/- 11.9 months after the empyema treatment. Three cases (12%) with a shorter mean follow-up (8.3 +/- 3.3 months) had minimal restrictive patterns. Six of 25 (24%) cases having pulmonary function tests were classified as stage 1, 12 (48%) as stage 2, and 7 (28%) as stage 3 empyema at admission. Of 25 cases having pulmonary function tests, 12 (48%) were treated with AB, 4 (16%) with AB+TT and 9 (36%) with AB+TT+FT. Mean VC, FVC, FEV1/FVC, FEV1, FEF25-75% and PEF values did not significantly differ according to stages and treatment modalities (p>0.05).Conclusion: It was seen that after the treatment of empyema, remarkable improvements were seen in chest roentgenographic findings between 3rd and 6th months and in general, pulmonary function tests revealed normal results in long term. Our results suggest that lung functions are not significantly compromised at long term after empyema treatment

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey

OZCELIK, HAYRIYE UGUR/0000-0003-1587-5216; Yilmaz, Ozge/0000-0001-6051-5020; Cekic, Sukru/0000-0002-9574-1842; Harmanci, Koray/0000-0002-8494-648X; Emiralioglu, Nagehan/0000-0002-1405-8401; Sismanlar Eyuboglu, Tugba/0000-0001-7284-4999; Aslan, Ayse Tana/0000-0002-5360-8517; COBANOGLU, NAZAN/0000-0002-3686-2927WOS: 000535323700001PubMed: 32453906Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs. Methods Data for age and genetic mutations from the Cystic Fibrosis Registry of Turkey collected in 2018 were used to find out the number of patients who are eligible for modulator therapy. Results of registered 1488 CF patients, genetic analysis was done for 1351. the numbers and percentages of patients and names of the drugs, that the patients are eligible for, are as follows: 122 (9.03%) for ivacaftor, 156 (11.54%) for lumacaftor-ivacaftor, 163 (11.23%) for tezacaftor-ivacaftor, and 57 (4.21%) for elexacaftor-tezacaftor-ivacaftor. Among 1351 genotyped patients total of 313 (23.16%) patients are eligible for currently licensed modulator therapies (55 patients were shared by ivacaftor and tezacaftor-ivacaftor, 108 patients were shared by lumacaftor-ivacaftor and tezacaftor-ivacaftor, and 22 patients were shared by tezacaftor-ivacaftor and elexacaftor-tezacaftor-ivacaftor groups). Conclusions the present study shows that approximately one-fourth of the registered CF patients in Turkey are eligible for modulator drugs. As, frequent mutations that CF patients have in Turkey are different from North American and European CF patients, developing modulator drugs effective for those mutations is necessary. Furthermore, as modulator drugs are very expensive currently, financial support of the government in developing countries like Turkey is noteworthy

Allergenic airborne gramineae (grass) pollen concentrations in Turkey

One of the most important allergens which cause allergic disease of upper and lower respiratory system is the effect of the airborne pollen grains belonging to Gramineae (Grass) family. In this compilation, it was pointed out that airborne pollen studies was carried out in Turkey and the monthly changes of allergenic Grass pollens rates for 51 regions of Turkey were presented as a calendar. In the studies carried out, the highest Grass pollen grains were recorded between april and august

Guideline for diagnosis and treament of food allergy in children by "academia of pediatric allergy and asthma society"

Food allergy is defined as type 1 hypersensitivity reaction of IgE antibodies against food proteins. As its frequency increases in the world, food allergy is becoming more common in our country. Infants, who have allergic rhinitis, bronchial asthma, atopic dermatitis and food allergy in their families, have a high risk of food allergy. Therefore defining a protocol will be helpful for correct diagnosis and treatment in high risk infants. The aim of this protocol prepared by "Academia of Pediatric Allergy and Asthma Society" is to asist the family physicians and pediatricians for the diagnosis and treatment of food allergy as a resource and guideline